Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255257 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAASAH1CYP19A1 | |
| SCHEMBL24000994 | 0.86 | NAMPT (0.47) | SMN1; SMN2 | |
| SCHEMBL10048209 | 0.85 | KMT2A (0.50) | SMN1; SMN2LMNAASAH1CYP19A1 | |
| SCHEMBL31737685 | 0.85 | CYP11B1 (0.46) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL23455649 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2ASAH1CYP19A1 | |
| SCHEMBL9591695 | 0.82 | RAB9A (0.51) | SMN1; SMN2CYP19A1 | |
| SCHEMBL4382438 | 0.81 | MLLT1 (0.58) | SMN1; SMN2LMNA | |
| SCHEMBL21340645 | 0.79 | LMNA (0.42) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL4615564 | 0.79 | NAMPT (0.51) | CA1CA2CYP19A1 | |
| SCHEMBL8875914 | 0.78 | RECQL (0.57) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2020-10-20 | — | — | US | disclosed |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PLIVA HRVATSKA D.O.O. (HR) | 2019-09-12 | — | — | US | disclosed |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2019-07-09 | — | — | US | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | SMN1; SMN2 2984/4885LMNA 992/4885ASAH1 1878/4885 |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | SMN1; SMN2 2984/4885LMNA 992/4885ASAH1 1878/4885 |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | SMN1; SMN2 2984/4885LMNA 992/4885ASAH1 1878/4885 |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | SMN1; SMN2 2984/4885LMNA 992/4885ASAH1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.